Business Model

Zymeworks is leveraging its novel antibody and alternative protein platforms to develop a diverse pipeline of novel antibody therapeutics that includes first-in-class and best-in-class candidates to help mitigate the risk and uncertainty associated with new target discovery and validation. Zymeworks intends to clinically develop a number of therapeutic candidates and plans to partner a subset once meaningful clinical inflection points are reached.

Zymeworks is also forming highly-strategic collaborative drug development partnerships with major pharmaceutical partners to provide them access to, while expanding and diversifying the therapeutic applications for, Zymeworks’ platforms. Throughout the lifespan of these programs Zymeworks benefits from upfront payments, near-term research and development milestones and long-term royalty streams.

Display page(s):